Results 1 to 10 of about 279 (77)

Validación del ClinESSDAI para Argentina

Revista Argentina de Reumatología, 2023
Introducción: recientemente, en Europa y en idioma inglés, se ha desarrollado el Clinical EULAR Sjögren's Syndrome Disease Activity Index (ClinESSDAI) para evaluar la actividad en pacientes con síndrome de Sjögren primario (SSp).
Julieta Silvana Morbiducci, María Florencia Rodríguez, Patricia Sasaki, Agustina Cáceres, Lucía Alascio, Silvia Papasidero, Sinda Zalles, Julia Demarchi, Anastasia Secco   +8 more
doaj   +1 more source

Bloqueo capsular versus bloqueo IPACK: Comparación en el manejo del dolor en pacientes con reemplazo total de rodilla

Revista Científica CMDLT, 2022
Objetivo: Evaluar la eficacia del bloqueo capsular versus bloqueo IPACK en el manejo del dolor en pacientes tratados con reemplazo total de rodilla.
Julio Alfonso García Hernández, Franco Cordivani Maloni   +1 more
doaj   +5 more sources

Tratamiento de la sialorrea con toxina botulinica en niños con paralisis cerebral

Revista Herediana de Rehabilitación, 2020
Objetivo: Determinar la utilidad de la toxina botulínica en el tratamiento de la sialorrea en niños con Parálisis Cerebral. Material y Métodos: Estudio Prospectivo experimental, longitudinal de cohorte y abierto.
Emma Rivera La Plata, Doris Reymer Reinoso, Helga Solis Mujica   +2 more
doaj   +1 more source

A randomised, double‐blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO‐524 in dogs with atopic dermatitis

Veterinary Dermatology, Volume 34, Issue 6, Page 523-531, December 2023., 2023
Background – Polyunsaturated fatty acids (PUFA) can be beneficial in the management of canine atopic dermatitis (cAD). A commercial product PCSO‐524 containing PUFA has demonstrated anti‐inflammatory effects in dogs. Hypothesis/Objectives – To evaluate the efficacy of PCSO‐524, in combination with oclacitinib in dogs with cAD.
Takeo Nishiyama, Masashi Kusakabe, Ichiro Imanishi, Tadashi Hisano, Teruyasu Fukamachi, Norihito Taguchi, Keita Iyori, Yun‐Hsia Hsiao   +7 more
wiley   +1 more source

A randomised controlled trial testing the rebound‐preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis

Veterinary Dermatology, Volume 34, Issue 2, Page 99-106, April 2023., 2023
Background – A rebound of pruritus occasionally occurs after oclacitinib dose reduction in dogs with atopic dermatitis (AD). Objectives – To determine whether an initial 4‐day course of prednisolone decreases the probability of a pruritus rebound after reducing the frequency of oclacitinib administration.
Thierry Olivry, Viktorija Lokianskiene, Alejandro Blanco, Pablo Del Mestre, Kerstin Bergvall, Luc Beco   +5 more
wiley   +1 more source

Dolor postoperatorio en cirugía de reparación del manguito rotador mini abierto y artroscópico bajo protocolo de analgesia multimodal

Revista Colombiana de Ortopedia y Traumatología, 2020
Introducción: La cirugía de manguito rotador ha mejorado los síntomas y la función asociada a las lesiones que no han respondido al manejo conservador, sin embargo, puede presentarse dolor severo e incomodidad en el postoperatorio requiriendo una ...
Luis José María Suárez, Guido Fierro P, Juan Carlos González G   +2 more
doaj   +1 more source

A randomised, double‐blinded comparison between subcutaneous rush and intralympathic allergen immunotherapy induction in atopic dogs

Veterinary Dermatology, Volume 34, Issue 2, Page 91-98, April 2023., 2023
Background – Atopic dermatitis (AD) is one of the most common skin diseases in small animal practice. Allergen immunotherapy (AIT) is the only curative treatment for the disease, and oral, subcutaneous and intralymphatic administration of allergens are commonly employed.
Ralf S. Mueller, Yuri Zablotski, Katja Baumann, Teresa Boehm, Bettina Kasper, Christoph Klinger, Maarten Monke, Laura Udraite‐Vovk, Tamara Weitzer, Natalie K. Y. Gedon   +9 more
wiley   +1 more source

The effect of a mixed cannabidiol and cannabidiolic acid based oil on client‐owned dogs with atopic dermatitis

Veterinary Dermatology, Volume 33, Issue 4, Page 329-e77, August 2022., 2022
Background– Cannabidiol (CBD) and cannabidiolic acid (CBDA) are reported to have antinociceptive, immunomodulatory and anti‐inflammatory actions. Objectives – To determine if CBD/CBDA is an effective therapy for canine atopic dermatitis (cAD). Conclusions and clinical relevance – Cannabidiol/CBDA as an adjunct therapy decreased pruritus, and not skin ...
Melissa Loewinger, Joseph J. Wakshlag, Daniel Bowden, Jeanine Peters‐Kennedy, Andrew Rosenberg   +4 more
wiley   +1 more source

A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client‐owned dogs with allergic dermatitis

Veterinary Dermatology, Volume 32, Issue 5, Page 477-e131, October 2021., 2021
Background – Interleukin (IL)‐31 is an important mediator in canine atopic dermatitis (cAD) and also may be dysregulated in other allergic diseases. Hypothesis/Objectives – To demonstrate the efficacy and safety of lokivetmab (canine anti‐IL‐31 monoclonal antibody) for treatment of pruritus associated with allergic dermatitis in dogs.
Leen Van Brussel, Hilde Moyaert, Monica Escalada, Sean P. Mahabir, Michael R. Stegemann   +4 more
wiley   +1 more source

Repeated onabotulinum neurotoxin A injections for drooling in children with neurodisability

Developmental Medicine &Child Neurology, Volume 63, Issue 8, Page 991-997, August 2021., 2021
Aim To evaluate the effect of repeated onabotulinum neurotoxin A injections for the treatment of drooling in children with neurodisabilities. Method This was a retrospective cohort study, in which the first, second, and third onabotulinum neurotoxin A injection were compared within children treated between 2000 and 2020.
Stijn Bekkers, Theresa YS Leow, Karen Van Hulst, Lynn B Orriëns, Arthur RT Scheffer, Frank JA Van Den Hoogen   +5 more
wiley   +1 more source